Antibacterial synergist 3 

Antibacterial synergist 3 is a dual-acting inhibitor of biofilm (IC₅₀ of PAO1: 0.40 μM and IC₅₀ of PA14: 1.45 μM). Antibacterial synergist 3 reduces virulence production by inhibiting the quorum sensing (QS) system and induces iron deficiency in P. aeruginosa PAO1. Antibacterial synergist 3 enhances the efficacy of Tobramycin (HY-B0441) and Ciprofloxacin (HY-B0356) in a mouse wound infection model. Antibacterial synergist 3 can be used for the research of P. aeruginosa infections^[1].

Antibacterial synergist 3 (compound JH21) (0.15625-2.5 μM) reduces the biofilm formation rate of P. aeruginosa PAO1 in a concentration-dependent manner^[1].
Antibacterial synergist 3 (0.3125-10 μM) reduces the production of P. aeruginosa virulence factors elastase (43%) and pyocyanin (42%), and decreases the production of biofilm matrix exopolysaccharides (58%)^[1].
Antibacterial synergist 3 (0.3125-10 μM) suppresses the fluorescence of PAO1-lasB-gfp and PAO1-pqsA-gfp strains but has no effect on the fluorescence of PAO1-gfp and its growth, indicating that it inhibits both the las and pqs systems^[1].
Antibacterial synergist 3 (0.3125-10 μM) reduces the iron content of P. aeruginosa PAO1 (57%)^[1].
Antibacterial synergist 3 (0.3125-10 μM) inhibits the swarming (84%) and swimming (64%) motility of P. aeruginosa PAO1 in a concentration-dependent manner^[1].
Antibacterial synergist 3 (1.25-40 μM) shows no significant hemolytic effect on mouse and rabbit erythrocytes, indicating that it has good biosafety^[1].
Antibacterial synergist 3 (1.25-100 μM) shows no cytotoxicity to RAW264.7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antibacterial synergist 3 (2.5 μM, topical, 3 d) combined with Tobramycin (HY-B0441) (0.0025 mg/mL) can reduce the survival rate of P. aeruginosa in the mouse wound infection model (0.97%) and significantly increase the antibacterial effect of Tobramycin (HY-B0441) (200 times)^[1].
Antibacterial synergist 3 (2.5 μM, topical, 3 d) combined with Ciprofloxacin (HY-B0356) (0.001 mg/mL) can reduce the survival rate of P. aeruginosa in the mouse wound infection model (0.45%) and significantly increase the antibacterial effect of Ciprofloxacin (HY-B0356) (1000 times)^[1].
Antibacterial synergist 3 (0-100 μM, 0-120 h) does not affect the survival rate of zebrafish larvae (100%) in the zebrafish model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

352.41

C₁₅H₂₀N₄O₄S

ONC(CCCCNC(CNC1=NC2=CC=C(C=C2S1)OC)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang ZM, et al. Hybrid Molecules of Benzothiazole and Hydroxamic Acid as Dual-Acting Biofilm Inhibitors with Antibacterial Synergistic Effect against Pseudomonas aeruginosa Infections. J Med Chem. 2025 Mar 27;68(6):6210-6232.  [Content Brief]